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WPE3
HEALTH ECONOMISTS AND MANAGED CARE 
DECISION-MAKERS: BRIDGING THE GAP
Bala MV1, Westrick E2, Mauskopf JA3
1Centocor, Inc., Malvern, PA, USA; 2MIM Health Plans, 
Providence, RI, USA; 3Research Triangle Institute, Research 
Triangle Park, NC, USA
WORKSHOP OBJECTIVE: The objective of this work-
shop is to demonstrate, using an interactive format, what
will make pharmacoeconomics more useful to managed
care decision-makers.
PARTICIPANTS WHO WOULD BENEFIT: Analysts or
decision-makers involved in the conduct or evaluation of
pharmacoeconomic studies.
Even though substantial investments are being made in
funding health economics studies, there is not much evi-
dence that the results of these studies are being effectively
used in decision-making within managed care organiza-
tions. In this workshop we examine potential reasons for
this disconnect between health economists and managed
care decision-makers by engaging in a discussion among
two health economists, a managed care decision-maker
and the workshop participants. The managed care deci-
sion-maker will describe the tools, such as formulary ex-
clusions, formulary restrictions with prior authorization
requirement, and treatment guidelines, that managed
care organizations use to enforce prescription of cost-
effective medications by their member physicians. He will
also describe what drug value information is used in de-
veloping these tools. The health economists will then
present potential modifications to standard pharmaco-
economic analyses that will allow managed care decision-
makers to integrate study results into these tools. They
will illustrate this using results of two new drug valuation
analyses, a cost-effectiveness analysis and a population
cost and outcome study. The managed care decision-
maker will then lead the workshop participants in a dis-
cussion about how each of these analyses could be useful
for making decisions about the new drugs. The discus-
sion will also focus on what further work would need to
be done to increase the value of the studies.
WPE9
BEGIN WITH THE END IN MIND: ISSUES IN 
PLANNING PHARMACOECONOMIC RESEARCH 
FOR MORE EFFECTIVE COMMUNICATION
Rindress D, Goetghebeur M, Welner S, McTavish A
BioMedCom Consultants inc, Montréal, Québec, Canada
WORKSHOP OBJECTIVE: This workshop has three ob-
jectives: 1) to illustrate the importance of early planning
of communication strategy for pharmacoeconomic re-
search; 2) to explore audience analysis as a tool in phar-
macoeconomic research planning; and 3) to examine the
persuasive impact of various types of communication on
decision-makers.
PARTICIPANTS WHO WOULD BENEFIT: Any re-
searcher in health outcomes and health economics with an
interest in augmenting the acceptability of their research to
and its persuasive impact on their target audience(s).
While considerable thought and resources are routinely
invested in the planning and conduct of pharmacoeco-
nomic research, the communication of research results is
often only considered long after the data has been com-
piled and analyzed. The purpose of this workshop is to
discuss how early planning of communication strategies,
including analysis of the target audience, may increase the
acceptability and usability of the research itself. Practical
experience in pharmacoeconomic communication and tra-
ditional communication and decision-making (not model-
ing) concepts are combined to stimulate new approaches
to effective practical research communication. A few inter-
active exercises will be included to illustrate the concepts
discussed. Participants should leave with greater aware-
ness of the issues surrounding communication planning
and some practical strategies for increasing the usefulness
of their work to end-users.
WTG1
APPLES AND APPLES, APPLES AND ORANGES: 
THE USE AND ABUSE OF AVERAGE DAILY DOSE 
IN PHARMACOECONOMIC RESEARCH
Loosbrock D1, Gibson J1, Dulisse B1,2, Edgell E3, Kody M3
1Health Outcomes Evaluation Group, Eli Lilly and Company, 
Indianapolis, IN, USA; 2Statistical and Mathematical Sciences, Eli 
Lilly and Company, Indianapolis, IN, USA; 3Global Health 
Outcomes Research, Eli Lilly and Company, Indianapolis, IN, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop is to develop skills to critically assess pharmacoeco-
nomic studies which compare daily dose or drug costs, by
considering the impact of differential population charac-
teristics, and by evaluating statistical methods often used
to address the differences.
PARTICIPANTS WHO WOULD BENEFIT: Developers
of treatment guidelines, medical directors, and formulary
decision-makers.
Pharmacoeconomic research often uses an average daily
dose to summarize drug costs. However, different antipsy-
chotic drugs differ significantly in their relative use for dif-
ferent diagnoses, age groups, or disease severity, which has
a marked affect on their average daily dose. It is mislead-
ing to compare average doses and consequent cost when
the compared populations have different distributions of
diagnosis, severity, or age, yet many non-randomized
pharmacoeconomic studies do not adequately control for
these factors. This workshop will prepare the audience to
assess such pharmacoeconomic studies more carefully,
both by clarifying the impact of differential population
characteristics, and by evaluating statistical methods often
used to address the differences. Physician survey data,
claims data, and observational study data will be used to
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demonstrate the impact of population characteristics on
mean antipsychotic dose. We will compare results using
different techniques to adjust average dose for population
differences. Techniques presented will include stratifica-
tion, limiting study population variation, and various mul-
tivariate regression coding and modeling strategies. We
discuss which techniques provide the greatest generaliz-
ability and the most valid comparisons.
WTG6
MAKING DECISIONS ABOUT
ANTIBIOTIC RESISTANCE
Davey PG
MEMO, Dundee, Scotland
WORKSHOP OBJECTIVE: Antibiotic resistance is an in-
creasing global problem and there is no doubt that it is
caused by antibiotic prescribing. Nonetheless, most pre-
scribing necessarily occurs at a time when it is uncertain
whether the patient has bacterial infection, never mind what
organism is causing the infection. The prescriber faces two
problems: 1) Which drug should I select in order to maxi-
mize this patient’s chance of recovery? (e.g., at what level of
trimethoprim resistance in Escherichia coli should I switch
to quinolones as my first line treatment for simple cystitis in
primary care?). 2) What impact does my choice of prescrib-
ing have on the prevalence of antibiotic resistance? (e.g., if I
recommend carbapenems for first-line treatment of sus-
pected intra-abdominal infection, will I be storing up future
trouble by increasing the prevalence of carbapenem resis-
tant bacteria in the hospital?). These two questions highlight
a conflict of interest that is at the heart of all healthcare de-
cision-making (Sabin, Br Med J 1998; 317:1002–4): the
competing duties of fidelity (to the individual patient) versus
stewardship (prudent allocation of scarce resources).
PARTICIPANTS WHO SHOULD ATTEND: Research-
ers and decision-makers with responsibility for antimi-
crobial prescribing. However, the issues raised are rele-
vant to the whole debate about priority setting.
The workshop will focus on two contrasting problems:
management of simple cystitis in primary care and man-
agement of intra-abdominal sepsis in hospitals. A generic
decision tree and influence diagram will be used as the
basis for discussion. Participants will be asked to identify
the key chance nodes that should influence decision-mak-
ing, and consider potential sources of information about
probabilities and utilities. The authors will share infor-
mation derived from two ongoing research projects.
WDM1
CURRENT COMPUTER SOFTWARE 
AND HARDWARE OPTIONS IN
PHARMACOECONOMICS: SPREADSHEETS, 
DECISION ANALYSIS, INTERNET, AND 
EDUCATIONAL TOOLS
McGhan WF
University of the Sciences in Philadelphia, Philadelphia, PA, USA
WORKSHOP OBJECTIVE: At the end of this session,
participants will be able to compare and contrast various,
current software and hardware options for pharmacoeco-
nomics and outcomes research.
PARTICIPANTS WHO WOULD BENEFIT: This ses-
sion is intended for individuals who have a basic under-
standing of the concepts used in pharmacoeconomic
analyses who wish to learn more about computer soft-
ware and hardware options.
Pharmacoeconomic analysis software programs should al-
low data and results to be examined from different policy
perspectives: 1) patient, 2) provider, 3) hospital, 4) payer,
and 5) society. Software models should also allow the as-
sessment of the healthcare interventions or services from
different quantitative perspectives: 1) cost of illness, 2)
cost-minimization, 3) cost-benefit, 4) cost-effectiveness,
and 5) cost-utility. Decision trees and sensitivity analysis
software will be reviewed. Programming options include
spreadsheet macros, visual basic, and Web page authoring
tools. Software programs will be demonstrated that can be
utilized on various hardware platforms including desk-
tops, laptops, and remote handhelds. Software applica-
tions can assist in analyzing data, present findings, or edu-
cate providers and patients. More software is becoming
available that facilitates assessment and incorporation of
patient preferences and quality of life scores into therapy
decision-making for treatment protocol development and
interfacing at the patient’s bedside. Questions that should
be asked in evaluating software include: How much of the
model is built on rigorous clinical trial data? Has the soft-
ware been peer reviewed and field tested? Are any ques-
tionnaires valid and reliable? Is the information well ref-
erenced? Can sensitivity and incremental analyses be
performed? Software and hardware options will be dem-
onstrated. Pros and cons of diverse analytical and soft-
ware approaches will be examined.
WMM1
IS THE CURRENT RELIANCE ON THE
MARKOV ASSUMPTION IN ECONOMIC
MODELS JUSTIFIED?
Caro JJ, Huybrechts KF
Caro Research, Boston, MA, USA
WORKSHOP OBJECTIVE: The objective of this work-
shop is to demonstrate why the willingness to rely on the
Markov restriction in economic models may not be justi-
fied and to suggest alternative approaches.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers involved in the development of health economic mod-
els, as well as those responsible for evaluating models.
Markov processes were first described by the Russian
mathematician Markov at the beginning of this century.
His intent was to generalize classical properties of se-
quences of independent random variables to sequences
not fulfilling the independence assumption. A Markov
